Project aims to raise awareness for pain research.
In an effort to educate the public about pain research and its impact on over 51.6 million Americans living with chronic pain, the US Pain Foundation has started an initiative to highlight the need for more research to improve outcomes. Titled #PainTrials, the endeavor will focus on current pain research efforts — including those being conducted through the National Institutes of Health's Helping to End Addiction Long-term® (HEAL) initiative.
According to a company press release, the organization hopes to:
"This month, we are excited to delve into the importance of pain research, and the impact research has on improved health outcomes for the millions of Americans living with the daily challenges of chronic pain," said Nicole Hemmenway, CEO, the US Pain Foundation. "We are excited to collaborate with the NIH HEAL Initiative, prominent researchers, and Humana to share the importance of pain research. A greater focus on research is vital to increase understanding and action surrounding chronic pain."
Reference: #PainTrials Initiative Seeks To Raise Awareness About The Need For Pain Research. PR Newswire. September 1, 2023. Accessed September 8, 2023. https://www.prnewswire.com/news-releases/paintrials-initiative-seeks-to-raise-awareness-about-the-need-for-pain-research-301914228.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.